Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

Published:2020-06-16 Issue:7 Volume:4 Page:1073-1086
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatol Commun

Author:

Choi Won‐Mook¹^ORCID,Choi Jonggi¹^ORCID,Lee Danbi¹,Shim Ju Hyun¹^ORCID,Lim Young‐Suk¹^ORCID,Lee Han Chu¹,Chung Young‐Hwa¹,Lee Young‐Sang¹,Park Sook Ryun²,Ryu Min‐Hee²,Ryoo Baek‐Yeol²,Lee So Jung³,Kim Kang Mo¹

Affiliation:

1. Department of Gastroenterology Liver Center University of Ulsan College of Medicine Seoul Republic of Korea

2. Department of Oncology University of Ulsan College of Medicine Seoul Republic of Korea

3. Department of Radiology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.1523

Reference36 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Epidemiology of liver cancer in South Korea

3. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma

4. Global trends and predictions in hepatocellular carcinoma mortality

5. Sorafenib in Advanced Hepatocellular Carcinoma

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Efficacy and Safety between Immune Checkpoint Inhibitors and Targeted Drugs in Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis;Combinatorial Chemistry & High Throughput Screening;2024-06-12

2. The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis;Expert Review of Anticancer Therapy;2024-04-16

3. Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review;Journal of Cancer Research and Clinical Oncology;2024-02-06

4. Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma;Yonsei Medical Journal;2024

5. From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.;Annals of Hepatology;2023-12